featured
Venetoclax and Low-Dose Cytarabine for Measurable Residual Disease or Oligoblastic Relapse in Patients With AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
J. Clin. Oncol 2024 Mar 01;[EPub Ahead of Print], IS Tiong, DK Hiwase, E Abro, A Bajel, E Palfreyman, A Beligaswatte, J Reynolds, N Anstee, T Nguyen, S Loo, CC Chua, M Ashby, KM Wiltshire, S Fleming, CY Fong, TC Teh, P Blombery, R Dillon, A Ivey, AH WeiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.